mRNA-1574
/ Moderna
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
July 28, 2023
A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants
(clinicaltrials.gov)
- P1 | N=108 | Active, not recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Oct 2023 ➔ Jun 2027
Trial completion date • Human Immunodeficiency Virus • Infectious Disease • CD4
February 08, 2023
A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants
(clinicaltrials.gov)
- P1 | N=108 | Active, not recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Suspended ➔ Active, not recruiting
Enrollment closed • Human Immunodeficiency Virus • Infectious Disease • CD4
February 03, 2023
A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants
(clinicaltrials.gov)
- P1 | N=108 | Suspended | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting ➔ Suspended
Trial suspension • Human Immunodeficiency Virus • Infectious Disease • CD4
October 03, 2022
A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants
(clinicaltrials.gov)
- P1 | N=108 | Active, not recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting ➔ Active, not recruiting
Enrollment closed • Human Immunodeficiency Virus • Infectious Disease • CD4
1 to 4
Of
4
Go to page
1